Each year, over one million patients worldwide die of peritoneal or pleural cancer – a condition often consecutive to advanced stomach, bowel or gynaecological cancers. There is no truly effective therapy available nor are there anti-cancer drugs available that are specifically developed for aerosolization in a patient’s abdominal cavity or hollow organs.

CapnoPharm’s mission is to make a difference in treating these cancer patients by researching, developing, producing, and distributing game-changing, specifically designed, re-formulated and intra-abdominally aerosolized drugs and drug-device combinations.

Our expertise in surgically-applied therapeutic aerosols offers numerous opportunities for research in and beyond the field of oncology.